SlideShare une entreprise Scribd logo
1  sur  65
TRAUMA DUE TO TREATMENT Prof.S.Ramaswamy’s unit,M1 Dr.Sangeetha.C.Joseph
Case  ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
History of presenting complaints ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
History of presenting complaints (contd.) ,[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
On Examination ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
CNS ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
INVESTIGATIONS ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
1.7 2.1 3.64 4.65 INR 21 21.2 22.4 21.3 aPTT Control-21 12.1 18.2 38.4 40.7 PT Control-11 DAY 8 DAY 6 DAY 3 DAY 1 INV
[object Object],[object Object],[object Object],[object Object]
 
[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object]
[object Object]
HEMOSTASIS ,[object Object],[object Object],[object Object],[object Object]
WHEN DOES BLOOD COAGULATE? ,[object Object],[object Object],[object Object]
INITIATION OF BLOOD COAGULATION Extrinsic Pathway Tissue trauma Leakage of Tissue Factor X Xa Prothrombin activator Ca +2 ,   factor VII Ca +2 Prothrombin    Thrombin (factor II) Ca +2 Intrinsic Pathway Blood trauma/ contact with collagen Activation of  factor XII, IX, VIII X Xa Ca +2 Prothrombin activator Prothrombin   Thrombin (factor II) Activation of certain factors (VII, II, X and protein C and S) is essential for coagulation. This activation requires vit K (reduced form)
Vitamin K-Dependent Clotting Factors Vitamin K Synthesis of Functional Coagulation Factors VII IX X II
Warfarin Mechanism of Action Warfarin Synthesis of Non Functional Coagulation Factors Antagonism of Vitamin K Vitamin K VII IX X II
WARFARIN: MECHANISM OF ACTION Inactive factors II, VII, IX, and X Proteins  S and C Proteins  S and C Active factors II, VII, IX, and X Vitamin K epoxide Vitamin K reduced WARFARIN ,[object Object],[object Object]
PLASMA HALF-LIVES OF VITAMIN K-DEPENDENT PROTEINS Peak anticoagulant effect may be delayed by 72 to 96 hours 36h Factor X 24h Factor IX 6h Factor VII 72h Factor II
Warfarin - Pathophysiology ,[object Object],[object Object],[object Object],[object Object]
INDICATIONS ,[object Object],[object Object],[object Object],[object Object],[object Object]
WHY TO MONITOR WARFARIN THERAPY? ,[object Object],[object Object]
MONITORING OF WARFARIN THERAPY ,[object Object],[object Object],[object Object]
PROTHROMBIN TIME (PT) ,[object Object],[object Object],[object Object],[object Object],[object Object]
PROBLEMS WITH PT/PTR ,[object Object],[object Object],[object Object]
INTERNATIONAL NORMALISED RATIO (INR) INR = [PT pt ]  ISI   [PT Ref ] PT pt  – prothrombin time of patient PT Ref  – prothrombin time of normal pooled sample ISI – International Sensitivity Index
OPTIMIZING WARFARIN THERAPY ,[object Object],[object Object],[object Object],[object Object],[object Object]
How frequently we should monitor? ,[object Object],[object Object],[object Object]
Commencement & discontinuation of AC  guidelines british committee for hematology ,[object Object],[object Object],[object Object]
Guide lines for dosing RECOMMENDATIONS american college of cardiology ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
 
OPTIMAL THERAPEUTIC RANGE 2.0-3.0 2.5-3.5  (high risk patients) Myocardial infarction,recurrent DVT and PTE 2.0-3.0 2.5-3.5 Heart valve replacement Bioprosthetic valve Mechanical valve 2.0-3.0 Mitral valve stenosis 2.0-3.0 Atrial fibrillation 2.0-3.0 Treatment of venous thromboembolism 2.0-3.0 Prophylaxis of venous thromboembolism INR Indication
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],2.5 2.5 2.5 2.5 / 3.0 2.5 2.5 3.0 – 3.5 2.5 – 3.0 2.5 Target INR . Warfarin Indications – Systemic
Usually indefinite Oral Anticoagulation for prevention of   Thromboembolism   ,[object Object],[object Object],[object Object],[object Object],[object Object],INR – 2 to 3 INR – 2.5 to 3.5 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Oral Anticoagulants inAtrial Fibrillation
FACTORS INFLUENCING DOSE RESPONSE ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
CONTARINDICATIONS AND PRECAUTIONS ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
SIDE EFFECTS ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Bleeding risk high in elderly d/t ,[object Object],[object Object],[object Object]
Etiology in elderly ,[object Object],[object Object]
May begin  concomitantly with Heparin  Therapy Heparin should be continued for a minimum of four days Time to peak antithrombotic effect of Warfarin  therapy is delayed 96 hours (despite INR) When INR reaches desired therapeutic range, discontinue heparin ( after a minimum of four days ) Conversion from Heparin to Warfarin
SWITCHOVER FROM ONE BRAND OF WARFARIN TO ANOTHER/ ACENOCOUMAROL ,[object Object],[object Object]
Signs of Warfarin Overdosage ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Causes of excessive anticoagulation ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
THE OVERALL ANTICOAGULATION QUALITY IS SIGNIFICANTLY BETTER WITH WARFARIN AS COMPARED TO ACENOCOUMAROL 72% 67% 64% 66% 68% 70% 72% %  Responders Warfarin Acenocoumarol Thrombosis And Haemostasis 1994; 71(2): 188-191
New Anticoagulation Drugs ,[object Object],[object Object],[object Object],[object Object],[object Object]
Why do we need new anticoagulation drugs? ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Synthetic Pentasaccharide ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Ximelagatran ,[object Object],[object Object],[object Object],[object Object],[object Object]
Dilemma for the physician in SDH ,[object Object],[object Object],[object Object]
Neurological complications of ac ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
How safely and for how long can W be withheld in pts when admitted with major bleeds ? ,[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object]
[object Object],[object Object]
Withdrawal of oral anticoagulant treatment ,[object Object],[object Object],[object Object],[object Object],[object Object]
Discontinuation of ac british committee  standards of hematology ,[object Object],[object Object],[object Object],[object Object],[object Object]
Reversal Options ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object]
Recommendations for reversal guide lines on oral ac by british society of hematology ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],Message  ……
[object Object]

Contenu connexe

Tendances

Tendances (20)

Implantable Cardiac Devices
Implantable Cardiac Devices Implantable Cardiac Devices
Implantable Cardiac Devices
 
ATRIAL FIBRILLATION 2016
ATRIAL FIBRILLATION 2016ATRIAL FIBRILLATION 2016
ATRIAL FIBRILLATION 2016
 
Arrhythmia Recognition & Management
Arrhythmia Recognition & ManagementArrhythmia Recognition & Management
Arrhythmia Recognition & Management
 
Mechanical Circulatory Support.pptx
Mechanical Circulatory Support.pptxMechanical Circulatory Support.pptx
Mechanical Circulatory Support.pptx
 
CHA2DS2-VASc, Score CHADS2 score, and Hasbled score
CHA2DS2-VASc,  Score CHADS2 score, and Hasbled scoreCHA2DS2-VASc,  Score CHADS2 score, and Hasbled score
CHA2DS2-VASc, Score CHADS2 score, and Hasbled score
 
HF update 2021
HF update 2021HF update 2021
HF update 2021
 
Mitral regurgitation by dr kalpana chetia
Mitral regurgitation by dr kalpana chetiaMitral regurgitation by dr kalpana chetia
Mitral regurgitation by dr kalpana chetia
 
Atrial fibrillation
Atrial fibrillationAtrial fibrillation
Atrial fibrillation
 
Vpcs
VpcsVpcs
Vpcs
 
Constrictive pericarditis
Constrictive pericarditisConstrictive pericarditis
Constrictive pericarditis
 
Diastolic Dysfunction 2016
Diastolic Dysfunction 2016Diastolic Dysfunction 2016
Diastolic Dysfunction 2016
 
Atrial Fibrillation by Dr. Aryan
Atrial Fibrillation by Dr. AryanAtrial Fibrillation by Dr. Aryan
Atrial Fibrillation by Dr. Aryan
 
Ischemic Heart Disease
Ischemic Heart DiseaseIschemic Heart Disease
Ischemic Heart Disease
 
MVP Mitral Valve Prolapse - Echocardiographic Evaluation
 MVP Mitral Valve  Prolapse - Echocardiographic Evaluation MVP Mitral Valve  Prolapse - Echocardiographic Evaluation
MVP Mitral Valve Prolapse - Echocardiographic Evaluation
 
Coarctation of aorta.
Coarctation of aorta.Coarctation of aorta.
Coarctation of aorta.
 
Atrial fibrillation
Atrial fibrillation Atrial fibrillation
Atrial fibrillation
 
Atrial tachycardia
Atrial tachycardiaAtrial tachycardia
Atrial tachycardia
 
VALVULAR HEART DISEASE
VALVULAR HEART DISEASEVALVULAR HEART DISEASE
VALVULAR HEART DISEASE
 
Cardiac Arrhythmias
Cardiac ArrhythmiasCardiac Arrhythmias
Cardiac Arrhythmias
 
Arrhythmia - Pathophysiology and Treatment (Pharmacotherapy)
Arrhythmia - Pathophysiology and Treatment (Pharmacotherapy) Arrhythmia - Pathophysiology and Treatment (Pharmacotherapy)
Arrhythmia - Pathophysiology and Treatment (Pharmacotherapy)
 

Similaire à A Case of Warfarin induced SDH

Case presentation
Case presentation  Case presentation
Case presentation
EM OMSB
 
Lec 12 management of rheumatic fever rheumatic heart disease for mohs
Lec 12 management of rheumatic fever   rheumatic heart disease for mohsLec 12 management of rheumatic fever   rheumatic heart disease for mohs
Lec 12 management of rheumatic fever rheumatic heart disease for mohs
EhealthMoHS
 
Management of cyanotic congenital heart diseae3
Management of  cyanotic congenital heart diseae3Management of  cyanotic congenital heart diseae3
Management of cyanotic congenital heart diseae3
Sandip Gupta
 

Similaire à A Case of Warfarin induced SDH (20)

Treatment of venous thrombosis and pulmonary embolism
Treatment of venous thrombosis and pulmonary embolism Treatment of venous thrombosis and pulmonary embolism
Treatment of venous thrombosis and pulmonary embolism
 
Bleeding disorders.pdf
Bleeding disorders.pdfBleeding disorders.pdf
Bleeding disorders.pdf
 
Pulmonary hypertension
Pulmonary hypertensionPulmonary hypertension
Pulmonary hypertension
 
Atrial fibrillation ksaus hs 2019
Atrial fibrillation ksaus hs 2019Atrial fibrillation ksaus hs 2019
Atrial fibrillation ksaus hs 2019
 
A Case of RHD with MI
A Case of RHD with MIA Case of RHD with MI
A Case of RHD with MI
 
Anticoagulant in surgery
Anticoagulant in surgeryAnticoagulant in surgery
Anticoagulant in surgery
 
Case 2: Pulmonary Thromboembolism
Case 2: Pulmonary ThromboembolismCase 2: Pulmonary Thromboembolism
Case 2: Pulmonary Thromboembolism
 
Case presentation
Case presentation  Case presentation
Case presentation
 
Preoperative evaluation for adult cardiac surgry
Preoperative evaluation for adult cardiac surgryPreoperative evaluation for adult cardiac surgry
Preoperative evaluation for adult cardiac surgry
 
Lec 12 management of rheumatic fever rheumatic heart disease for mohs
Lec 12 management of rheumatic fever   rheumatic heart disease for mohsLec 12 management of rheumatic fever   rheumatic heart disease for mohs
Lec 12 management of rheumatic fever rheumatic heart disease for mohs
 
principles of preoperative evaluation and preparation.pptx
principles of preoperative evaluation and preparation.pptxprinciples of preoperative evaluation and preparation.pptx
principles of preoperative evaluation and preparation.pptx
 
HYPERTENSION EMERGENCY & URGENCY
HYPERTENSION EMERGENCY & URGENCYHYPERTENSION EMERGENCY & URGENCY
HYPERTENSION EMERGENCY & URGENCY
 
hypertension anesthesia, general management. antihypertensive pharmacology
hypertension anesthesia, general management. antihypertensive pharmacologyhypertension anesthesia, general management. antihypertensive pharmacology
hypertension anesthesia, general management. antihypertensive pharmacology
 
Current management of Spontaneous intracerebral haemorrhage 2016
Current management of Spontaneous intracerebral haemorrhage 2016Current management of Spontaneous intracerebral haemorrhage 2016
Current management of Spontaneous intracerebral haemorrhage 2016
 
Medicine 5th year, 11th lecture/part one (Dr. Sabir)
Medicine 5th year, 11th lecture/part one (Dr. Sabir)Medicine 5th year, 11th lecture/part one (Dr. Sabir)
Medicine 5th year, 11th lecture/part one (Dr. Sabir)
 
Coagulants and anticoagulants.pptx
Coagulants and anticoagulants.pptxCoagulants and anticoagulants.pptx
Coagulants and anticoagulants.pptx
 
Pulmonary embolism
Pulmonary embolismPulmonary embolism
Pulmonary embolism
 
Atrial fibrillation (af)
Atrial fibrillation (af)Atrial fibrillation (af)
Atrial fibrillation (af)
 
Management of cyanotic congenital heart diseae3
Management of  cyanotic congenital heart diseae3Management of  cyanotic congenital heart diseae3
Management of cyanotic congenital heart diseae3
 
Cardiovascular Drugs
Cardiovascular Drugs Cardiovascular Drugs
Cardiovascular Drugs
 

Plus de Stanley Medical College, Department of Medicine

Plus de Stanley Medical College, Department of Medicine (20)

Interpretation of Liver Function Tests
Interpretation of Liver Function TestsInterpretation of Liver Function Tests
Interpretation of Liver Function Tests
 
A Case of Sheehan's Syndrome
A Case of Sheehan's SyndromeA Case of Sheehan's Syndrome
A Case of Sheehan's Syndrome
 
Imaging: Cortical Vein Thrombosis
Imaging: Cortical Vein ThrombosisImaging: Cortical Vein Thrombosis
Imaging: Cortical Vein Thrombosis
 
ECG: Findings in CNS disorders
ECG: Findings in CNS disordersECG: Findings in CNS disorders
ECG: Findings in CNS disorders
 
A Case of Arrhythmogenic Right Ventricular Dysplasia - ARVD
A Case of Arrhythmogenic Right Ventricular Dysplasia - ARVDA Case of Arrhythmogenic Right Ventricular Dysplasia - ARVD
A Case of Arrhythmogenic Right Ventricular Dysplasia - ARVD
 
A Case of NASH with HYPOTHYROIDISM
A Case of NASH with HYPOTHYROIDISMA Case of NASH with HYPOTHYROIDISM
A Case of NASH with HYPOTHYROIDISM
 
IMAGING: NEUROCYSTICERCOSIS
IMAGING: NEUROCYSTICERCOSISIMAGING: NEUROCYSTICERCOSIS
IMAGING: NEUROCYSTICERCOSIS
 
ECG: Digitalis Effect / MAT / AF
ECG: Digitalis Effect / MAT / AFECG: Digitalis Effect / MAT / AF
ECG: Digitalis Effect / MAT / AF
 
Imaging: BOOP
Imaging: BOOPImaging: BOOP
Imaging: BOOP
 
ECG: Hypokalemia
ECG: HypokalemiaECG: Hypokalemia
ECG: Hypokalemia
 
A Case of Idiopathic Pulmonary Hypertension
A Case of Idiopathic Pulmonary HypertensionA Case of Idiopathic Pulmonary Hypertension
A Case of Idiopathic Pulmonary Hypertension
 
A Case of Schmidt Syndrome
A Case of Schmidt Syndrome A Case of Schmidt Syndrome
A Case of Schmidt Syndrome
 
A Case of Rodenticide Poisoning
A Case of Rodenticide PoisoningA Case of Rodenticide Poisoning
A Case of Rodenticide Poisoning
 
A Case of Emphysematous Pylonephritis
A Case of Emphysematous Pylonephritis A Case of Emphysematous Pylonephritis
A Case of Emphysematous Pylonephritis
 
Imaging: Multiple Pulmonary Cavitary Lesions
Imaging: Multiple Pulmonary Cavitary LesionsImaging: Multiple Pulmonary Cavitary Lesions
Imaging: Multiple Pulmonary Cavitary Lesions
 
ECG: Atrial Dissociation
ECG: Atrial DissociationECG: Atrial Dissociation
ECG: Atrial Dissociation
 
A Case of Hepato-Pulmonary Syndrome
A Case of Hepato-Pulmonary SyndromeA Case of Hepato-Pulmonary Syndrome
A Case of Hepato-Pulmonary Syndrome
 
A Case of Thalassemia
A Case of ThalassemiaA Case of Thalassemia
A Case of Thalassemia
 
A Case of Renal Amyloidosis
A Case of Renal AmyloidosisA Case of Renal Amyloidosis
A Case of Renal Amyloidosis
 
CXR: Silico-Tuberculosis
CXR: Silico-TuberculosisCXR: Silico-Tuberculosis
CXR: Silico-Tuberculosis
 

Dernier

THORACOTOMY . SURGICAL PERSPECTIVES VOL 1
THORACOTOMY . SURGICAL PERSPECTIVES VOL 1THORACOTOMY . SURGICAL PERSPECTIVES VOL 1
THORACOTOMY . SURGICAL PERSPECTIVES VOL 1
DR SETH JOTHAM
 
Sonia Journal club presentation (2).pptx
Sonia Journal club presentation (2).pptxSonia Journal club presentation (2).pptx
Sonia Journal club presentation (2).pptx
palsonia139
 

Dernier (20)

Cardiovascular Physiology - Regulation of Cardiac Pumping
Cardiovascular Physiology - Regulation of Cardiac PumpingCardiovascular Physiology - Regulation of Cardiac Pumping
Cardiovascular Physiology - Regulation of Cardiac Pumping
 
5CL-ADB powder supplier 5cl adb 5cladba 5cl raw materials vendor on sale now
5CL-ADB powder supplier 5cl adb 5cladba 5cl raw materials vendor on sale now5CL-ADB powder supplier 5cl adb 5cladba 5cl raw materials vendor on sale now
5CL-ADB powder supplier 5cl adb 5cladba 5cl raw materials vendor on sale now
 
Cas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best suppler
Cas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best supplerCas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best suppler
Cas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best suppler
 
Hemodialysis: Chapter 2, Extracorporeal Blood Circuit - Dr.Gawad
Hemodialysis: Chapter 2, Extracorporeal Blood Circuit - Dr.GawadHemodialysis: Chapter 2, Extracorporeal Blood Circuit - Dr.Gawad
Hemodialysis: Chapter 2, Extracorporeal Blood Circuit - Dr.Gawad
 
Cervical screening – taking care of your health flipchart (Vietnamese)
Cervical screening – taking care of your health flipchart (Vietnamese)Cervical screening – taking care of your health flipchart (Vietnamese)
Cervical screening – taking care of your health flipchart (Vietnamese)
 
Hepar Sulphuris Remedy, Homoeopathic Materia Medica, HMM, 1st BhMS
Hepar Sulphuris Remedy, Homoeopathic Materia Medica, HMM, 1st BhMSHepar Sulphuris Remedy, Homoeopathic Materia Medica, HMM, 1st BhMS
Hepar Sulphuris Remedy, Homoeopathic Materia Medica, HMM, 1st BhMS
 
CT scan of penetrating abdominopelvic trauma
CT scan of penetrating abdominopelvic traumaCT scan of penetrating abdominopelvic trauma
CT scan of penetrating abdominopelvic trauma
 
Presentació "Advancing Emergency Medicine Education through Virtual Reality"
Presentació "Advancing Emergency Medicine Education through Virtual Reality"Presentació "Advancing Emergency Medicine Education through Virtual Reality"
Presentació "Advancing Emergency Medicine Education through Virtual Reality"
 
Muscle Energy Technique (MET) with variant and techniques.
Muscle Energy Technique (MET) with variant and techniques.Muscle Energy Technique (MET) with variant and techniques.
Muscle Energy Technique (MET) with variant and techniques.
 
Denture base resins materials and its mechanism of action
Denture base resins materials and its mechanism of actionDenture base resins materials and its mechanism of action
Denture base resins materials and its mechanism of action
 
5cladba raw material 5CL-ADB-A precursor raw
5cladba raw material 5CL-ADB-A precursor raw5cladba raw material 5CL-ADB-A precursor raw
5cladba raw material 5CL-ADB-A precursor raw
 
SURGICAL ANATOMY OF ORAL IMPLANTOLOGY.pptx
SURGICAL ANATOMY OF ORAL IMPLANTOLOGY.pptxSURGICAL ANATOMY OF ORAL IMPLANTOLOGY.pptx
SURGICAL ANATOMY OF ORAL IMPLANTOLOGY.pptx
 
THORACOTOMY . SURGICAL PERSPECTIVES VOL 1
THORACOTOMY . SURGICAL PERSPECTIVES VOL 1THORACOTOMY . SURGICAL PERSPECTIVES VOL 1
THORACOTOMY . SURGICAL PERSPECTIVES VOL 1
 
CURRENT HEALTH PROBLEMS AND ITS SOLUTION BY AYURVEDA.pptx
CURRENT HEALTH PROBLEMS AND ITS SOLUTION BY AYURVEDA.pptxCURRENT HEALTH PROBLEMS AND ITS SOLUTION BY AYURVEDA.pptx
CURRENT HEALTH PROBLEMS AND ITS SOLUTION BY AYURVEDA.pptx
 
In-service education (Nursing Mangement)
In-service education (Nursing Mangement)In-service education (Nursing Mangement)
In-service education (Nursing Mangement)
 
TUBERCULINUM-2.BHMS.MATERIA MEDICA.HOMOEOPATHY
TUBERCULINUM-2.BHMS.MATERIA MEDICA.HOMOEOPATHYTUBERCULINUM-2.BHMS.MATERIA MEDICA.HOMOEOPATHY
TUBERCULINUM-2.BHMS.MATERIA MEDICA.HOMOEOPATHY
 
PREPARATION FOR EXAMINATION FON II .pptx
PREPARATION FOR EXAMINATION FON II .pptxPREPARATION FOR EXAMINATION FON II .pptx
PREPARATION FOR EXAMINATION FON II .pptx
 
TEST BANK For Timby's Introductory Medical-Surgical Nursing, 13th Edition by ...
TEST BANK For Timby's Introductory Medical-Surgical Nursing, 13th Edition by ...TEST BANK For Timby's Introductory Medical-Surgical Nursing, 13th Edition by ...
TEST BANK For Timby's Introductory Medical-Surgical Nursing, 13th Edition by ...
 
TEST BANK For Huether and McCance's Understanding Pathophysiology, Canadian 2...
TEST BANK For Huether and McCance's Understanding Pathophysiology, Canadian 2...TEST BANK For Huether and McCance's Understanding Pathophysiology, Canadian 2...
TEST BANK For Huether and McCance's Understanding Pathophysiology, Canadian 2...
 
Sonia Journal club presentation (2).pptx
Sonia Journal club presentation (2).pptxSonia Journal club presentation (2).pptx
Sonia Journal club presentation (2).pptx
 

A Case of Warfarin induced SDH

  • 1. TRAUMA DUE TO TREATMENT Prof.S.Ramaswamy’s unit,M1 Dr.Sangeetha.C.Joseph
  • 2.
  • 3.
  • 4.
  • 5.
  • 6.
  • 7.
  • 8.
  • 9.
  • 10. 1.7 2.1 3.64 4.65 INR 21 21.2 22.4 21.3 aPTT Control-21 12.1 18.2 38.4 40.7 PT Control-11 DAY 8 DAY 6 DAY 3 DAY 1 INV
  • 11.
  • 12.  
  • 13.
  • 14.
  • 15.
  • 16.
  • 17.
  • 18. INITIATION OF BLOOD COAGULATION Extrinsic Pathway Tissue trauma Leakage of Tissue Factor X Xa Prothrombin activator Ca +2 , factor VII Ca +2 Prothrombin Thrombin (factor II) Ca +2 Intrinsic Pathway Blood trauma/ contact with collagen Activation of factor XII, IX, VIII X Xa Ca +2 Prothrombin activator Prothrombin Thrombin (factor II) Activation of certain factors (VII, II, X and protein C and S) is essential for coagulation. This activation requires vit K (reduced form)
  • 19. Vitamin K-Dependent Clotting Factors Vitamin K Synthesis of Functional Coagulation Factors VII IX X II
  • 20. Warfarin Mechanism of Action Warfarin Synthesis of Non Functional Coagulation Factors Antagonism of Vitamin K Vitamin K VII IX X II
  • 21.
  • 22. PLASMA HALF-LIVES OF VITAMIN K-DEPENDENT PROTEINS Peak anticoagulant effect may be delayed by 72 to 96 hours 36h Factor X 24h Factor IX 6h Factor VII 72h Factor II
  • 23.
  • 24.
  • 25.
  • 26.
  • 27.
  • 28.
  • 29. INTERNATIONAL NORMALISED RATIO (INR) INR = [PT pt ] ISI [PT Ref ] PT pt – prothrombin time of patient PT Ref – prothrombin time of normal pooled sample ISI – International Sensitivity Index
  • 30.
  • 31.
  • 32.
  • 33.
  • 34.  
  • 35. OPTIMAL THERAPEUTIC RANGE 2.0-3.0 2.5-3.5 (high risk patients) Myocardial infarction,recurrent DVT and PTE 2.0-3.0 2.5-3.5 Heart valve replacement Bioprosthetic valve Mechanical valve 2.0-3.0 Mitral valve stenosis 2.0-3.0 Atrial fibrillation 2.0-3.0 Treatment of venous thromboembolism 2.0-3.0 Prophylaxis of venous thromboembolism INR Indication
  • 36.
  • 37.
  • 38.
  • 39.
  • 40.
  • 41.
  • 42.
  • 43.
  • 44. May begin concomitantly with Heparin Therapy Heparin should be continued for a minimum of four days Time to peak antithrombotic effect of Warfarin therapy is delayed 96 hours (despite INR) When INR reaches desired therapeutic range, discontinue heparin ( after a minimum of four days ) Conversion from Heparin to Warfarin
  • 45.
  • 46.
  • 47.
  • 48. THE OVERALL ANTICOAGULATION QUALITY IS SIGNIFICANTLY BETTER WITH WARFARIN AS COMPARED TO ACENOCOUMAROL 72% 67% 64% 66% 68% 70% 72% % Responders Warfarin Acenocoumarol Thrombosis And Haemostasis 1994; 71(2): 188-191
  • 49.
  • 50.
  • 51.
  • 52.
  • 53.
  • 54.
  • 55.
  • 56.
  • 57.
  • 58.
  • 59.
  • 60.
  • 61.
  • 62.
  • 63.
  • 64.
  • 65.

Notes de l'éditeur

  1. The four Vitamin K dependent clotting factors are synthesized in the liver.
  2. Warfarin acts as an anticoagulant by blocking the ability of Vitamin K to carboxylate the Vitamin K dependent clotting factors, thereby reducing their coagulant activity.
  3. The signs of warfarin overdosage are listed on this slide. Hemorrhagic complications from warfarin therapy are more likely to occur with excessive degrees of anticoagulation, but even with an INR in the therapeutic range, bleeding can occur. Because of the likelihood of finding an underlying lesion in an individual who has gastrointestinal bleeding or significant genito-urinary bleeding in the face of therapeutic levels of anticoagulation, one is advised to consider and evaluate for underlying abnormalities predisposing to the bleeding. The return on such evaluations in the face of an excessive degree of anticoagulation diminishes, and one must use judgement whether or not to pursue an evaluation.